PMID- 29032273
OWN - NLM
STAT- MEDLINE
DCOM- 20190308
LR  - 20190308
IS  - 1523-6536 (Electronic)
IS  - 1083-8791 (Linking)
VI  - 24
IP  - 1
DP  - 2018 Jan
TI  - Torquetenovirus Dynamics and Immune Marker Properties in Patients Following 
      Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Longitudinal 
      Study.
PG  - 194-199
LID - S1083-8791(17)30763-2 [pii]
LID - 10.1016/j.bbmt.2017.09.020 [doi]
AB  - Torquetenovirus (TTV) has been proposed as a marker of immune function in 
      patients receiving immunosuppression after solid organ transplantation. This 
      study aimed to define TTV plasma dynamics and investigate clinical associations 
      in patients following allogeneic hematopoietic stem cell transplantation (HSCT). 
      This was a single-center prospective longitudinal study involving 50 consecutive 
      patients treated with HSCT between March 2015 and April 2016. TTV plasma DNA 
      levels were measured with quantitative PCR at 12 consecutive time points during 
      the first year after HSCT. Forty of the 50 patients (80%) had detectable TTV 
      viremia before HSCT (median level, 5.37 log10 copies/mL; interquartile range 
      [IQR], 3.51-6.44 log10 copies/mL). All patients subsequently developed TTV 
      viremia during the follow-up period. Plasma viral loads evolved dynamically over 
      time, with a peak of 8.32 log10 copies/mL (IQR, 7.33-9.35 log10 copies/mL) 
      occurring at 79 days (IQR, 50-117 days) following HSCT and a stable plateau 
      toward the end of the follow-up period. The type of malignancy, the use of 
      antithymocyte globulin during conditioning, and the occurrence of acute 
      graft-versus-host disease requiring systemic therapy had temporary effects on TTV 
      dynamics. TTV levels showed a significant correlation with absolute lymphocyte 
      counts following engraftment (r(s) = -.27; P < .01) and with cytomegalovirus 
      (CMV; r(s)=.39; P < .01) and Epstein-Barr virus (EBV; r(s)=.45; P = .02) viral 
      loads during phases of viremia. Immune-related clinical events were not predicted 
      by TTV levels. TTV viremia occurred universally and was sustained throughout the 
      first year after HSCT. Several variables and events before and after HSCT were 
      correlated with TTV levels and hint toward immune marker properties of TTV, but 
      their complex interactions might perturb the capability of TTV to predict 
      immune-related complications in this population.
CI  - Copyright (c) 2017 The American Society for Blood and Marrow Transplantation. 
      Published by Elsevier Inc. All rights reserved.
FAU - Wohlfarth, Philipp
AU  - Wohlfarth P
AD  - Division of Blood and Marrow Transplantation, Department of Medicine I, Medical 
      University of Vienna, Vienna, Austria. Electronic address: 
      philipp.wohlfarth@medunwien.ac.at.
FAU - Leiner, Michael
AU  - Leiner M
AD  - Division of Blood and Marrow Transplantation, Department of Medicine I, Medical 
      University of Vienna, Vienna, Austria.
FAU - Schoergenhofer, Christian
AU  - Schoergenhofer C
AD  - Department of Clinical Pharmacology, Medical University of Vienna, Vienna, 
      Austria.
FAU - Hopfinger, Georg
AU  - Hopfinger G
AD  - Division of Blood and Marrow Transplantation, Department of Medicine I, Medical 
      University of Vienna, Vienna, Austria.
FAU - Goerzer, Irene
AU  - Goerzer I
AD  - Department of Virology, Medical University of Vienna, Vienna, Austria.
FAU - Puchhammer-Stoeckl, Elisabeth
AU  - Puchhammer-Stoeckl E
AD  - Department of Virology, Medical University of Vienna, Vienna, Austria.
FAU - Rabitsch, Werner
AU  - Rabitsch W
AD  - Division of Blood and Marrow Transplantation, Department of Medicine I, Medical 
      University of Vienna, Vienna, Austria.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171012
PL  - United States
TA  - Biol Blood Marrow Transplant
JT  - Biology of blood and marrow transplantation : journal of the American Society for 
      Blood and Marrow Transplantation
JID - 9600628
RN  - 0 (Biomarkers)
RN  - 0 (DNA, Viral)
SB  - IM
MH  - Adult
MH  - Biomarkers/*analysis/blood
MH  - Cytomegalovirus
MH  - DNA Virus Infections/blood/immunology
MH  - DNA, Viral/blood
MH  - Female
MH  - Hematopoietic Stem Cell Transplantation/*adverse effects
MH  - Herpesvirus 4, Human
MH  - Humans
MH  - Longitudinal Studies
MH  - Lymphocyte Count
MH  - Male
MH  - Prospective Studies
MH  - Torque teno virus/*physiology
MH  - Transplantation, Homologous/adverse effects
MH  - Viral Load
OTO - NOTNLM
OT  - HSCT
OT  - Hematopoietic stem cell transplantation
OT  - TTV
OT  - Torquetenovirus
EDAT- 2017/10/17 06:00
MHDA- 2019/03/09 06:00
CRDT- 2017/10/17 06:00
PHST- 2017/08/03 00:00 [received]
PHST- 2017/09/28 00:00 [accepted]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2019/03/09 06:00 [medline]
PHST- 2017/10/17 06:00 [entrez]
AID - S1083-8791(17)30763-2 [pii]
AID - 10.1016/j.bbmt.2017.09.020 [doi]
PST - ppublish
SO  - Biol Blood Marrow Transplant. 2018 Jan;24(1):194-199. doi: 
      10.1016/j.bbmt.2017.09.020. Epub 2017 Oct 12.